Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways - Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S; Wallace, Daniel J; Dow, Ernst R; Higgs, Richard E; Rocha, Guilherme; Crowe, Brenda; Benschop, Robert J; Byers, Nicole L; Silk, Maria E; et al. (Lupus Science & Medicine, 2020)
Keywords: Adult; Arthritis; autoimmune diseases; Azetidines; Azetidines - therapeutic use; Clinical trials; Clinical Trials and Drug Discovery; Cytokines; Drug dosages; Female; Gene Expression; Humans; Immunologic diseases. Allergy; Kinases; Lupus; lupus erythematosus; Lupus Erythematosus, Systemic; Lupus Erythematosus, Systemic - drug therapy; Male; Middle Aged; Pathogenesis; Patients; Purines; Purines - therapeutic use; Pyrazoles; Pyrazoles - therapeutic use; RC581-607; Sulfonamides; Sulfonamides - therapeutic use; systemic; therapeutics; autoimmune diseases; systemic; therapeutics; cytokines; lupus erythematosus